Skip to main content

Chronic Obstructive Pulmonary Disease News (Page 4)

Related terms: Chronic Obstructive Pulmonary Disease, Acute, Bronchitis, Chronic, Bronchitis with Airway Obstruction, Chronic Bronchitis, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease, COPD, Acute, COPD, Maintenance, Emphysema, Chronic Obstructive Pulmonary Disease, Maintenance, COPD

FDA Approves Duaklir Pressair (aclidinium bromide and formoterol fumarate) for Maintenance Treatment of Chronic Obstructive Pulmonary Disease

Oxford, UK – 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Dr...

FDA Approves ProAir Digihaler (albuterol sulfate) as the First and Only Digital Inhaler with Built-In Sensors

JERUSALEM--(BUSINESS WIRE)--Dec 21, 2018--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir ® Digihaler™ (a...

FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD)

DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ – Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today...

Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD

24 April 2018 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy...

FDA Medwatch Alert: Long-Acting Beta agonists (LABAs) and Inhaled Corticosteroids (ICS): Drug Safety Communication - Boxed Warning About Asthma-Related Death Removed

ISSUE: FDA's most prominent warning, the Boxed Warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. A FDA review of four large...

Sunovion Receives FDA Approval for Lonhala Magnair (glycopyrrolate) Inhalation Solution to Treat COPD

MARLBOROUGH, Mass.--(BUSINESS WIRE) December 5, 2017 --Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application...

FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD

London UK – 18 September 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single i...

Bevespi Aerosphere Approved by the FDA for Patients with COPD

25 April 2016 – AstraZeneca today announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the...

FDA Approves Seebri Neohaler (glycopyrrolate) for COPD

EAST HANOVER, N.J., Oct. 29, 2015 Novartis announced today that the US Food and Drug Administration (FDA) has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 mcg as a stand-alone...

FDA Approves Utibron Neohaler (indacaterol/glycopyrrolate) for COPD

EAST HANOVER, N.J., Oct. 29, 2015 Novartis announced today that the US Food and Drug Administration (FDA) has approved the dual combination bronchodilator Utibron Neohaler...

FDA Approves Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for COPD

RIDGEFIELD, Conn., May 26, 2015 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) I...

FDA Approves Spiriva Respimat (tiotropium) for the Maintenance Treatment of COPD

Ridgefield, Conn., September 25, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat (tiotropium bromide) i...

FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease

July 31, 2014 – Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including...

FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD

London UK - 30 April 2014, GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the...

FDA Approves Anoro Ellipta to Treat Chronic Obstructive Pulmonary Disease

December 18, 2013 – The U.S. Food and Drug Administration today approved Anoro Ellipta (umeclidinium and vilanterol inhalation powder) for the once-daily, long-term maintenance treatment of airflow...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related drug support groups

prednisone, albuterol, Symbicort, Trelegy Ellipta, montelukast, Anoro Ellipta